PD-1 inhibitor blocks both PD-L1 and PD-L2, whereas PD-L1 inhibitor also blocks the binding to CD80 which releases CTLA-4-mediated anti-tumor immunity (27, 28). Here, PDCD1LG2 is linked to neoplasm.